Last updated: 2026-09-07 06:15:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ionis Pharmaceuticals, Inc. (IONS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $58.09, with a market capitalization of $9.65B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $50.01 to $86.74. This page covers its latest market performance, valuation, price trends and company information.
$9.65B | |
$58.36 | |
$86.74 | |
$19.59 | |
$58.13 | |
1.73M | |
3.01M | |
-- | |
$86.74 | |
$50.01 | |
-- | |
-- |
Ionis Pharmaceuticals, Inc. (IONS) last closed at $58.13 as of 2026-09-05 00:00:00, unchanged from the previous close of $58.13.
During the latest regular trading session, IONS traded between $19.59 and $86.74, with a volume of 1.73M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Ionis Pharmaceuticals, Inc. (IONS) moved from $62.43 to $58.09, representing a decline of 6.95% ($4.34).
The stock traded between $57.47 and $63.48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.32 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.0%
IONS is currently trading at $58.09, placing it 22.0% of the way from its 52-week low of $50.01 to its 52-week high of $86.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1402 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ionis Pharmaceuticals, Inc. (IONS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.